- Home
- FICO vs CANF Comparison
FICO vs CANF Comparison
Compare FICO & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FICO
- CANF
- Stock Information
- Founded
- FICO 1956
- CANF 1994
- Country
- FICO United States
- CANF Israel
- Employees
- FICO N/A
- CANF N/A
- Industry
- FICO Business Services
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- FICO Consumer Discretionary
- CANF Health Care
- Exchange
- FICO Nasdaq
- CANF Nasdaq
- Market Cap
- FICO 44.5B
- CANF 13.5M
- IPO Year
- FICO 1987
- CANF N/A
- Fundamental
- Price
- FICO $1,543.55
- CANF $1.03
- Analyst Decision
- FICO Buy
- CANF Strong Buy
- Analyst Count
- FICO 12
- CANF 2
- Target Price
- FICO $2,228.00
- CANF $14.00
- AVG Volume (30 Days)
- FICO 328.2K
- CANF 146.4K
- Earning Date
- FICO 07-30-2025
- CANF 08-29-2025
- Dividend Yield
- FICO N/A
- CANF N/A
- EPS Growth
- FICO 21.78
- CANF N/A
- EPS
- FICO 23.21
- CANF N/A
- Revenue
- FICO $1,840,361,000.00
- CANF $674,000.00
- Revenue This Year
- FICO $17.67
- CANF $461.72
- Revenue Next Year
- FICO $15.78
- CANF N/A
- P/E Ratio
- FICO $66.53
- CANF N/A
- Revenue Growth
- FICO 14.71
- CANF N/A
- 52 Week Low
- FICO $1,484.29
- CANF $0.98
- 52 Week High
- FICO $2,402.52
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- FICO 28.93
- CANF 43.30
- Support Level
- FICO $1,520.00
- CANF $1.00
- Resistance Level
- FICO $1,905.33
- CANF $1.09
- Average True Range (ATR)
- FICO 91.99
- CANF 0.03
- MACD
- FICO -30.04
- CANF 0.00
- Stochastic Oscillator
- FICO 5.60
- CANF 45.00
About FICO Fair Isaac Corproation
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).